Evidence map›Paper›PMID 27504637›Full record

Trial reportPLoS medicine2016

Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial.

Collins C Iwuji, Joanna Orne-Gliemann, Joseph Larmarange, Nonhlanhla Okesola, Frank Tanser, Rodolphe Thiebaut, Claire Rekacewicz, Marie-Louise Newell, Francois Dabis, ANRS 12249 TasP trial group

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PLoS medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01509508 (A Cluster Randomised Trial Comparing the Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence. The ARNS 12249 TasP), which is not on this map. Cited by 114 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 7 pooled it
18.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01509508 nacompletednot on this map

A Cluster Randomised Trial Comparing the Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence. The ARNS 12249 TasP (Treatment as Prevention) Trial in Hlabisa Sub-district, KwaZulu-Natal, South Africa.

TypeinterventionalSponsorANRS, Emerging Infectious DiseasesRan2012 to 2016Enrolled28,153ConditionsHIV InfectionArmsImmediate ARV treatment initiation with TDF/FTC/EFV, South African recommendation guided ARV (TDF/FTC/EFV) initiation
3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 7 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Rapid initiation of antiretroviral therapy for people living with HIV.The Cochrane database of systematic reviews · 2019
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Collins C IwujiAfrica Centre for Population Health, University of KwaZulu-Natal, Durban, South Africa.
Joanna Orne-GliemannCentre INSERM U1219 Bordeaux Population Health, Université de Bordeaux, Bordeaux, France.
Joseph LarmarangeAfrica Centre for Population Health, University of KwaZulu-Natal, Durban, South Africa.ORCID http://orcid.org/0000-0001-7097-700X
Nonhlanhla OkesolaAfrica Centre for Population Health, University of KwaZulu-Natal, Durban, South Africa.
Frank TanserAfrica Centre for Population Health, University of KwaZulu-Natal, Durban, South Africa.
Rodolphe ThiebautCentre INSERM U1219 Bordeaux Population Health, Université de Bordeaux, Bordeaux, France.
Claire RekacewiczAgence Nationale de Recherches sur le Sida et les Hépatites Virales, Paris, France.
Marie-Louise NewellAfrica Centre for Population Health, University of KwaZulu-Natal, Durban, South Africa.
Francois DabisCentre INSERM U1219 Bordeaux Population Health, Université de Bordeaux, Bordeaux, France.ORCID http://orcid.org/0000-0002-1614-8857
ANRS 12249 TasP trial group
Université de Bordeaux · FRUniversity of KwaZulu-Natal · ZAAgence Nationale de Recherches sur le Sida et les Hépatites Virales · FRMortimer Market Centre · GBUniversité Paris Cité · FRUniversity of Southampton · GB

Funding

Causal Pathways to population health impact of HIV antiretroviral treatmentR01HD084233 · NICHD · UNIVERSITY OF KWAZULU-NATAL · PI BARNIGHAUSEN, TILL, TANSER, FRANK COURTENEY · 2015 to 2021
$2.3M
NICHD NIH HHS R01 HD084233Wellcome Trust
6 · The paper itself

Abstract

backgroundThe 2015 WHO recommendation of antiretroviral therapy (ART) for all immediately following HIV diagnosis is partially based on the anticipated impact on HIV incidence in the surrounding population. We investigated this approach in a cluster-randomised trial in a high HIV prevalence setting in rural KwaZulu-Natal. We present findings from the first phase of the trial and report on uptake of home-based HIV testing, linkage to care, uptake of ART, and community attitudes about ART. METHODS AND

findingsBetween 9 March 2012 and 22 May 2014, five clusters in the intervention arm (immediate ART offered to all HIV-positive adults) and five clusters in the control arm (ART offered according to national guidelines, i.e., CD4 count ≤ 350 cells/μl) contributed to the first phase of the trial. Households were visited every 6 mo. Following informed consent and administration of a study questionnaire, each resident adult (≥16 y) was asked for a finger-prick blood sample, which was used to estimate HIV prevalence, and offered a rapid HIV test using a serial HIV testing algorithm. All HIV-positive adults were referred to the trial clinic in their cluster. Those not linked to care 3 mo after identification were contacted by a linkage-to-care team. Study procedures were not blinded. In all, 12,894 adults were registered as eligible for participation (5,790 in intervention arm; 7,104 in control arm), of whom 9,927 (77.0%) were contacted at least once during household visits. HIV status was ever ascertained for a total of 8,233/9,927 (82.9%), including 2,569 ascertained as HIV-positive (942 tested HIV-positive and 1,627 reported a known HIV-positive status). Of the 1,177 HIV-positive individuals not previously in care and followed for at least 6 mo in the trial, 559 (47.5%) visited their cluster trial clinic within 6 mo. In the intervention arm, 89% (194/218) initiated ART within 3 mo of their first clinic visit. In the control arm, 42.3% (83/196) had a CD4 count ≤ 350 cells/μl at first visit, of whom 92.8% initiated ART within 3 mo. Regarding attitudes about ART, 93% (8,802/9,460) of participants agreed with the statement that they would want to start ART as soon as possible if HIV-positive. Estimated baseline HIV prevalence was 30.5% (2,028/6,656) (95% CI 25.0%, 37.0%). HIV prevalence, uptake of home-based HIV testing, linkage to care within 6 mo, and initiation of ART within 3 mo in those with CD4 count ≤ 350 cells/μl did not differ significantly between the intervention and control clusters. Selection bias related to noncontact could not be entirely excluded.

conclusionsHome-based HIV testing was well received in this rural population, although men were less easily contactable at home; immediate ART was acceptable, with good viral suppression and retention. However, only about half of HIV-positive people accessed care within 6 mo of being identified, with nearly two-thirds accessing care by 12 mo. The observed delay in linkage to care would limit the individual and public health ART benefits of universal testing and treatment in this population.

trial registrationClinicalTrials.gov NCT01509508.

Indexed as

Attitude to HealthContinuity of Patient CareAdultAIDS SerodiagnosisAnti-HIV AgentsFemaleHIV InfectionsHumansMaleMiddle AgedRural PopulationSelf CareSexual PartnersSouth AfricaYoung AdultAnti-HIV Agents

Identifiers

PMID27504637
PMCPMC4978506
OpenAlexW2508191793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.